Galecto, Inc. (NASDAQ: GLTO) is a clinical-stage biotechnology company dedicated to the discovery and development of precision medicines that address serious fibrotic and oncological diseases. The company’s research focuses on the galectin family of proteins, particularly galectin-3, which plays a key role in tissue remodeling, fibrosis and tumor progression. By targeting galectin pathways, Galecto aims to deliver novel therapies that can modify the course of progressive diseases with high unmet medical needs.
Galecto’s lead clinical programs include GB0139, an inhaled small molecule inhibitor of galectin-3 for the treatment of idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases, and GB1211, an orally administered galectin-3 inhibitor being evaluated in various solid tumors and fibrotic conditions. In addition to its core pipeline, Galecto invests in preclinical research to expand its portfolio into other indications where galectin-driven mechanisms are implicated, such as liver fibrosis and cancer-related desmoplasia.
Since its founding in 2011 as a spin-out from Lund University in Sweden, Galecto has built a multidisciplinary team of scientists, clinicians and regulatory experts. The company completed its initial public offering on the Nasdaq Capital Market in 2020, reinforcing its commitment to advancing late-stage clinical trials and forging strategic collaborations. Galecto maintains research facilities in Malmö, Sweden, and corporate headquarters in Copenhagen, Denmark, with a subsidiary in the United States to support clinical development and regulatory engagement.
Under the leadership of President and Chief Executive Officer Hans Schambye, Galecto has established partnerships with academic institutions and biopharmaceutical companies worldwide to accelerate its translational programs. The organization’s governance is supported by a board of directors with extensive experience in drug development, commercialization and finance, positioning Galecto to navigate the complexities of bringing first-in-class therapies to patients globally.
AI Generated. May Contain Errors.
